EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome

Ryosuke Oki, Tetsuya Urasaki, Arisa Ueki, Kentaro Inamura, Yoshinobu Komai, Shunji Takahashi, Junji Yonese, Takeshi Yuasa iD

IJU Case Reports · 2023-01 · 6 (1) · 33-36

DOI: 10.1002/iju5.12542 ↗

Kurz gefasst

Fallbericht in der Zeitschrift IJU Case Reports, online erschienen am 28.10.2022. Verfasst von Ryosuke Oki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In Lynch syndrome, urothelial cancer is the third most common cancer, following colorectal and endometrial cancers. Little is known, however, about the efficacy of immune checkpoint inhibitors in the treatment of metastatic urothelial cancer in Lynch syndrome. Case presentation A 49‐year‐old patient with metastatic urothelial cancer underwent pembrolizumab therapy after platinum‐containing chemotherapy. The efficacy of the pembrolizumab therapy was good. Her lung and bone metastatic lesions disappeared in imaging studies and her back pain decreased dramatically. Pathogenic mutations of MSH2 and BRCA2 were found in the DNA extracted from her tumor, and subsequent genetic analysis confirmed the germline pathogenic variant of MSH2. As such, this case was genetically diagnosed as Lynch syndrome.

Conclusion

We report metastatic urothelial cancer in a patient with Lynch syndrome who demonstrated a radiological complete response to pembrolizumab therapy. Accurate genetic diagnosis can provide useful information to both the patient and their relatives.

Schlagwörter

Stichwörter der Autor:innen

Lynch syndromeimmune checkpoint inhibitormetastatic urothelial cancermismatch repair genespembrolizumab

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
  • Department of Clinical Genetic Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
  • Department of Pathology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
  • Department of Urology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.

ORCID-Profile: Takeshi Yuasa

Zitieren

APA

Oki, R., Urasaki, T., Ueki, A., Inamura, K., Komai, Y., Takahashi, S., Yonese, J., & Yuasa, T. (2023). A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome. IJU Case Reports, 6(1), 33-36. https://doi.org/10.1002/iju5.12542

Vancouver

Oki R, Urasaki T, Ueki A, Inamura K, Komai Y, Takahashi S, et al. A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome. IJU Case Reports. 2023;6(1):33-36. doi:10.1002/iju5.12542

BibTeX
@article{Oki2023,
  author = {Oki, Ryosuke and Urasaki, Tetsuya and Ueki, Arisa and Inamura, Kentaro and Komai, Yoshinobu and Takahashi, Shunji and Yonese, Junji and Yuasa, Takeshi},
  title = {A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome},
  journal = {IJU Case Reports},
  year = {2023},
  volume = {6},
  number = {1},
  pages = {33--36},
  doi = {10.1002/iju5.12542}
}
Kostenlos starten →